Loading…
Indogulf Cropsciences (IGCL)₹60.21−1.30%Pesticides & Agrochemicals
In the Jun 2026 quarter (consolidated), Indogulf Cropsciences reported sales of ₹169 Cr, down 11.0% from Jun 2025, and net profit of ₹2.42 Cr, down 37.6% year on year. For the year to Mar 2026, sales were ₹707 Cr and net profit ₹40.01 Cr.
Company filings, consolidated accounts; latest reported quarter Jun 2026
| Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 139 | 133 | 234 | 99.56 | 127 | 190 | 249 | 117 | 151 | 169 |
| Expenses | 119 | 127 | 206 | 89.48 | 106 | 180 | 217 | 105 | 131 | 159 |
| Operating Profit | 20.27 | 5.95 | 27.39 | 10.05 | 20.81 | 9.92 | 31.97 | 11.70 | 20.35 | 9.53 |
| OPM % | 14.7% | 4.5% | 11.8% | 10.2% | 16.5% | 5.3% | 12.9% | 10.1% | 13.5% | 5.7% |
| Other Income | 3.44 | 1.69 | 1.12 | 0.62 | 1.96 | 0.95 | 2.30 | 2.69 | 1.61 | 0.85 |
| Interest | 3.27 | 3.15 | 3.17 | 4.03 | 4.14 | 3.78 | 4.58 | 4.30 | 4.37 | 4.50 |
| Depreciation | 2.57 | 2.45 | 2.63 | 2.03 | 3.45 | 2.42 | 2.61 | 2.71 | 3.67 | 2.77 |
| Profit before tax | 17.91 | 2.05 | 22.75 | 4.62 | 15.20 | 4.66 | 27.16 | 7.39 | 13.95 | 3.13 |
| Tax % | 27.6% | 34.2% | 26.6% | 20.6% | 35.4% | 16.7% | 23.7% | 47.6% | 16.6% | 22.7% |
| Exceptional items | 1.02 | 0.83 | 0.05 | −0.01 | 0.00 | 0.00 | 0.24 | 0.07 | −0.26 | −0.01 |
| Net Profit | 12.95 | 1.36 | 16.68 | 3.67 | 9.81 | 3.88 | 20.70 | 3.87 | 11.62 | 2.42 |
| EPS (Rs) | 5.51 | 0.29 | 3.43 | 0.76 | 2.02 | 0.80 | 3.28 | 0.62 | 1.85 | 0.39 |
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|
| Sales | 444 | 487 | 552 | 553 | 592 | 707 | 686 |
| Expenses | 405 | 443 | 503 | 494 | 528 | 632 | 612 |
| Operating Profit | 38.92 | 44.96 | 48.94 | 58.89 | 63.88 | 73.94 | 73.55 |
| OPM % | 9.0% | 9.0% | 9.0% | 11.0% | 11.0% | 10.0% | 10.7% |
| Other Income | 2.01 | 4.01 | 2.99 | 0.00 | 5.01 | 7.99 | 7.45 |
| Interest | 4.99 | 5.99 | 11.98 | 12.99 | 14.98 | 16.98 | 17.75 |
| Depreciation | 5.98 | 7.97 | 9.97 | 9.96 | 10.96 | 10.97 | 11.76 |
| Profit before tax | 30.06 | 36.07 | 30.04 | 36.06 | 45.03 | 53.08 | 51.63 |
| Tax % | 25.9% | 25.9% | 26.0% | 21.9% | 28.9% | 24.9% | — |
| Exceptional items | −0.13 | 0.05 | 0.11 | −2.56 | 0.93 | 0.10 | 0.04 |
| Net Profit | 22.01 | 25.99 | 22.02 | 28.02 | 31.01 | 40.01 | 38.61 |
| EPS (Rs) | 9.49 | 11.26 | 9.54 | 12.02 | 6.46 | 6.34 | 6.14 |
| Dividend payout % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — |
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Equity Capital | 24.03 | 24.07 | 24.02 | 24.06 | 49.08 | 63.21 |
| Reserves | 130 | 158 | 181 | 209 | 227 | 397 |
| Borrowings | 79.18 | 102 | 195 | 160 | 228 | 184 |
| Other Liabilities | 179 | 140 | 121 | 155 | 189 | 182 |
| Total Liabilities | 412 | 423 | 521 | 546 | 692 | 826 |
| Fixed Assets | 51.13 | 53.06 | 69.16 | 48.06 | 47.08 | 49.08 |
| CWIP | 6.01 | 9.01 | 9.01 | 23.01 | 58.08 | 76.02 |
| Investments | 2.99 | 0.00 | 0.00 | 0.00 | 0.00 | 11.98 |
| Other Assets | 352 | 361 | 441 | 476 | 587 | 690 |
| Inventories | 168 | 153 | 210 | 196 | 271 | 344 |
| Trade receivables | 118 | 153 | 176 | 221 | 223 | 241 |
| Cash & equivalents | 5.98 | 4.98 | 3.99 | 2.99 | 9.98 | 11.98 |
| Total Assets | 412 | 423 | 521 | 546 | 692 | 826 |
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Cash from operating activity | 20.06 | −7.01 | −57.11 | 53.13 | −15.05 | −41.11 |
| Cash from investing activity | −9.96 | −9.96 | −18.91 | −4.98 | −39.85 | −36.85 |
| Cash from financing activity | −8.99 | 15.99 | 74.97 | −48.92 | 60.93 | 79.92 |
| Net cash flow | 1.01 | −1.01 | −1.01 | −1.01 | 7.01 | 3.01 |
| Capex | 11.04 | 13.05 | 20.08 | 25.08 | 42.14 | 28.10 |
| Free cash flow | 10.04 | −19.08 | −77.26 | 47.15 | −55.25 | −69.25 |
| CFO / OP % | 72.1% | 6.0% | −95.0% | 100.0% | −5.0% | −35.9% |
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Debtor days | 97 | 115 | 117 | 146 | 138 | 125 |
| Inventory days | 205 | 167 | 201 | 195 | 260 | 258 |
| Days payable | 139 | 112 | 80 | 110 | 130 | 97 |
| Cash conversion cycle | 164 | 171 | 239 | 232 | 268 | 286 |
| Working capital days | 63 | 87 | 92 | 112 | 115 | 159 |
| ROCE % | — | 16.0% | 12.0% | 13.0% | 13.0% | 12.0% |
For the Jun 2026 quarter, Indogulf Cropsciences reported sales of ₹169 Cr, down 11.0% year on year and net profit of ₹2.42 Cr, down 37.6% year on year. The operating margin was 5.7%.
Indogulf Cropsciences' sales for the year to Mar 2026 were ₹707 Cr; over the last twelve months they were ₹686 Cr.
Net profit for the year to Mar 2026 was ₹40.01 Cr, and ₹38.61 Cr over the last twelve months. Earnings per share over the same trailing period were ₹6.14.
Indogulf Cropsciences reported borrowings of ₹184 Cr at Mar 2026, against cash and equivalents of ₹11.98 Cr.
Cash from operations was −₹41.11 Cr in the year to Mar 2026; after capital spending, free cash flow was −₹69.25 Cr.